Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects
- 15 September 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 10 (10) , 2478-2487
Abstract
Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.Keywords
Funding Information
- Korea Health Industry Development Institute (HI14C1277(HR14C0003))
- National Research Foundation of Korea (NRF-2018M3A9H3024850, NRF-2018R1A2A1A05076997, NRF-2018R1A2A1A05079172)
This publication has 41 references indexed in Scilit:
- A dual tag system for facilitated detection of surface expressed proteins in Escherichia coliMicrobial Cell Factories, 2012
- Effect of Salmonella treatment on an implanted tumor (CT26) in a mouse modelJournal of Microbiology, 2012
- Drug delivery systems: An updated reviewInternational Journal of Pharmaceutical Investigation, 2012
- Decorating microbes: surface display of proteins on Escherichia coliTrends in Biotechnology, 2011
- Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli–mediated Cytolytic Therapy and RadiotherapyMolecular Therapy, 2010
- Influence of Promoter, Gene Copy Number, and Preexisting Immunity on Humoral and Cellular Responses to a Vectored Antigen Delivered by a Salmonella enterica VaccineClinical and Vaccine Immunology, 2009
- Toll-like receptors and cancerNature Reviews Cancer, 2008
- Targeted Therapy with aSalmonella TyphimuriumLeucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude MiceCancer Research, 2006
- Breaking down the barriers to cancer immunotherapyNature Immunology, 2005
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004